Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2009

 

 

CERUS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   0-21937   68-0262011

(State or other jurisdiction

of incorporation)

   (Commission File No.)  

(IRS Employer

Identification No.)

2411 Stanwell Drive

Concord, California 94520

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (925) 288-6000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

On August 19, 2009, Cerus Corporation (the “Company”) announced that the Swiss regulatory body, Swissmedic, has approved the use of platelet components treated with the Company’s INTERCEPT Blood System. A copy of the Company’s press release, entitled “Cerus’ INTERCEPT Blood System for Platelets Receives Swiss Approval,” is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

Number

   

Description

99.1    Press Release, dated August 19, 2009, entitled “Cerus’ INTERCEPT Blood System for Platelets Receives Swiss Approval.”

 

1.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CERUS CORPORATION
Dated: August 19, 2009     By:  

/s/    Kevin D. Green

      Kevin D. Green
     

Vice President, Finance and Chief

Accounting Officer

 

2.

EXHIBIT INDEX

 

Exhibit

Number

   

Description

99.1

    Press Release, dated August 19, 2009, entitled “Cerus’ INTERCEPT Blood System for Platelets Receives Swiss Approval.”

 

3.